Arslan, Çağatay

Profile Picture
Profile URL
https://hdl.handle.net/20.500.14365/7133
Name Variants
Arslan, C.
Arslan, C
Arslan, Cagatay MD
Arslan, Çagatay
Arslan, Cagatay
Arslan, Ç
Job Title
Email Address
cagatay.arslan@ieu.edu.tr
Main Affiliation
09.02. Internal Sciences
Status
Current Staff
Website
ORCID ID
0000-0002-3783-7432
Scopus Author ID
57191447331
Turkish CoHE Profile ID
CABA2717A5A8658C
Google Scholar ID
IitMzpoAAAAJ
WoS Researcher ID
I-1932-2016

Sustainable Development Goals

NO POVERTY1
NO POVERTY
0
Research Products
ZERO HUNGER2
ZERO HUNGER
0
Research Products
GOOD HEALTH AND WELL-BEING3
GOOD HEALTH AND WELL-BEING
35
Research Products
QUALITY EDUCATION4
QUALITY EDUCATION
0
Research Products
GENDER EQUALITY5
GENDER EQUALITY
0
Research Products
CLEAN WATER AND SANITATION6
CLEAN WATER AND SANITATION
0
Research Products
AFFORDABLE AND CLEAN ENERGY7
AFFORDABLE AND CLEAN ENERGY
0
Research Products
DECENT WORK AND ECONOMIC GROWTH8
DECENT WORK AND ECONOMIC GROWTH
0
Research Products
INDUSTRY, INNOVATION AND INFRASTRUCTURE9
INDUSTRY, INNOVATION AND INFRASTRUCTURE
0
Research Products
REDUCED INEQUALITIES10
REDUCED INEQUALITIES
0
Research Products
SUSTAINABLE CITIES AND COMMUNITIES11
SUSTAINABLE CITIES AND COMMUNITIES
0
Research Products
RESPONSIBLE CONSUMPTION AND PRODUCTION12
RESPONSIBLE CONSUMPTION AND PRODUCTION
0
Research Products
CLIMATE ACTION13
CLIMATE ACTION
0
Research Products
LIFE BELOW WATER14
LIFE BELOW WATER
2
Research Products
LIFE ON LAND15
LIFE ON LAND
0
Research Products
PEACE, JUSTICE AND STRONG INSTITUTIONS16
PEACE, JUSTICE AND STRONG INSTITUTIONS
0
Research Products
PARTNERSHIPS FOR THE GOALS17
PARTNERSHIPS FOR THE GOALS
0
Research Products
Documents

126

Citations

2340

h-index

23

Go to Scopus profile
Documents

73

Citations

580

Go to WoS profile
Scholarly Output

39

Articles

26

Views / Downloads

110/113

Supervised MSc Theses

0

Supervised PhD Theses

0

WoS Citation Count

317

Scopus Citation Count

303

Patents

0

Projects

0

WoS Citations per Publication

8.13

Scopus Citations per Publication

7.77

Open Access Source

14

Supervised Theses

0

JournalCount
Annals of Oncology5
Clinical Genitourinary Cancer4
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) -- MAY 30-JUN 03, 2025 -- Chicago, IL3
Journal of Clınıcal Oncology2
Cancer treatment reviews1
Current Page: 1 / 6

Scopus Quartile Distribution

Competency Cloud

GCRIS Competency Cloud

Filters

2021 - 202639
Reset filters

Settings

Scholarly Output Search Results

Now showing 1 - 10 of 39
  • Thumbnail Image
    Conference Object
    Citation - WoS: 1
    Two Randomized Controlled Trials of Romiplostim for Chemotherapy-Induced Thrombocytopenia in Patients With Solid Tumors
    (Amer Soc Hematology, 2022-11-15) Al-Samkari, Hanny; Geredeli, Caglayan; Arslan, Cagatay; Korantzis, Ippokratis; Dogu, Gamze Gokoz; Nechaeva, Marina; Fernandez, Mercedes Salgado; Soff, Gerald A.
    [Abstract Not Available]
  • Thumbnail Image
    Article
    Enhancing Outcomes in mCRPC: The Impact of Androgen Receptor Inhibitor Sequencing Before 177Lu-PSMA Therapy
    (Oxford Univ Press, 2025-07-22) Yazgan, Sati Coskun; Kayas, Kamil; Arslan, Cagatay; Kapar, Caner; Oztekin, Sura; Ceylan, Furkan; Urun, Yuksel
    Background Prostate-specific membrane antigen (PSMA) is a key target in metastatic castration resistance prostate cancer (mCRPC). Enzalutamide, an androgen receptor pathway inhibitor (ARPi), increases PSMA expression, potentially enhancing 177Lu-PSMA-617 radioligand therapy. This study evaluates the impact of prior ARPi (enzalutamide vs abiraterone acetate [AA]) on PSMA expression, PFS, and OS. Materials and Methods A retrospective analysis of 214 mCRPC patients treated with 177Lu-PSMA-617 across six Turkish centers (2015-2025) was conducted. Patients were grouped by prior ARPi therapy. PFS and OS were analyzed using Kaplan-Meier and Cox regression methods. Results Among 103 patients receiving ARPi before 177Lu-PSMA-617, 59 (57%) had enzalutamide and 44 (43%) AA. Median PFS was 7.6 months for enzalutamide versus 5.3 months for AA (P = .068). Median OS was significantly longer with enzalutamide (12.8 vs 6.9 months, P = .021). Patients with Eastern Cooperative Oncology Group Performance Scores (ECOG PS) 0-1 had significantly longer OS (27.6 vs 6.9 months for PS 2-3, P < .0001). Higher PSMA SUVmax (>20) correlated with longer OS (15.1 vs 7.8 months, P = .016). Among 86 patients with detectable PSMA SUVmax, 53 had SUVmax > 20; 66% had prior enzalutamide and 34% AA. Median OS was four months longer with enzalutamide (18.1 vs 13.9 months P = .120). Multivariate analysis identified ARPi type (HR: 2.24, P = .033) and ECOG PS (HR: 5.22, P < .0001) as independent OS predictors. Conclusion Enzalutamide prior to 177Lu-PSMA-617 significantly improves OS and enhances PSMA expression compared to AA. These findings highlight the importance of treatment sequencing in mCRPC and warrant further prospective studies.
  • Thumbnail Image
    Article
    Treatment Patterns and Attrition in Metastatic Renal Cell Carcinoma: Real-Life Experience From the Turkish Oncology Group Kidney Cancer Consortium (tkcc) Database
    (Cig Media Group, Lp, 2024) Bolek, Hatice; Sertesen, Elif; Kuzu, Omer Faruk; Tural, Deniz; Sim, Saadet; Sendur, Mehmet Ali Nahit; Urun, Yuksel; Arslan, Cagatay
    The inclusion of patients with more favorable prognoses in clinical trials imits generalizability to broader and more diverse patient group. This study examines treatment patterns and attrition rates in Turkish oncology clinics for metastatic renal cell carcinoma. The percentages of patients receiving treatment in the second, third, and fourth lines of therapy were 62.8%, 27.4%, and 8.9%, respectively. Disease progression was the primary cause of attrition, followed by toxicity. Introduction: Despite the rapid evolution in management of metastatic renal cell carcinoma (mRCC) over the past decade, challenges remain in accessing new therapies in some parts of the world. Despite therapeutic advancements, attrition rates remain persistently high. This study aims to assess the treatment patterns and attrition rates of patients with mRCC in oncology clinics across Turkey. Patients and Methods: Patients diagnosed with mRCC between January 1, 2008, and December 31, 2022, with first-line systemic treatment data, were retrospectively evaluated using the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database. Results: The final analysis included a total of 1126 patients. The percentages of patients treated in the 2nd, 3rd, 4th, and 5th lines of therapy were 62.8%, 27.4%, 8.9%, and 2.1%, respectively. The drugs that were most commonly used in the groups were tyrosine kinase inhibitors (TKIs) (52.2%) and interferon (IFN)-alpha (43.3%) for the first line, TKIs (66.3%) and immunotherapy (IO) monotherapy (25.9%) for the second line, TKI (41.4%) and mTOR inhibitors (28.8%) for the third line, TKI (44.4%) and mTOR inhibitors (29%) for the fourth line, and IO monotherapy (37.5%) and TKI (25%) for the fifth line. For the first-line treatment, the primary cause of attrition was disease progression (66.4%), followed by toxicity (16.5%), death (11.2%), and patient preference (5.9%). The primary reason for attrition across all treatment lines was disease progression. Over time, the use of TKIs in first-line treatment increased, while IFN-alpha usage declined. IOs began to be utilized in earlier lines, predominantly in second-line treatment, though use of IO-based combination therapies remains limited. Conclusion: This study underscores that despite significant progress in therapeutic options, the adoption of novel agents remains slow, and attrition rates are still high. These findings indicate a disparity in systemic therapy compared to developed countries.
  • Thumbnail Image
    Conference Object
    Long-Term Outcome and Safety in Patients Treated With Immune Checkpoint Blockade Therapies for Urothelial Carcinoma: Experience From Real-World Clinical Practice.
    (Lippincott Williams & Wilkins, 2022-02-20) Tural, Deniz; Arslan, Cagatay; Selcukbiricik, Fatih; Olmez, Omer Fatih; Erman, Mustafa; Urun, Yuksel; Karadurmus, Nuri; Kilickap, Saadettin
    [Abstract Not Available]
  • Thumbnail Image
    Conference Object
    Citation - WoS: 10
    Biomarker Analysis and Updated Results From the Phase Iii Propel Trial of Abiraterone (abi) and Olaparib (ola) Vs Abi and Placebo (pbo) as First-Line (1l) Therapy for Patients (pts) With Metastatic Castration-Resistant Prostate Cancer (mcrpc)
    (Elsevier, 2022) Saad, F.; Armstrong, A. J.; Thiery-Vuillemin, A.; Oya, M.; Shore, N. D.; Procopio, G.; Arslan, C.; Clarke, N.
    [Abstract Not Available]
  • Thumbnail Image
    Article
    The Efficacy of Immunotherapy and Chemoimmunotherapy in Patients With Advanced Rare Tumors: a Turkish Oncology Group (tog) Study
    (Wiley, 2023-12-22) Güven, Deniz Can; Aykan, Musa Barış; Muglu, Harun; Bayram, Ertuğrul; Helvacı, Kaan; Dursun, Bengue; Celayir, Melisa; Arslan, Çağatay; Kilickap, Saadettin
    Introduction: The advances in immune checkpoint inhibitors (ICIs) were relatively slow in rare tumors. Therefore, we conducted a multi-center study evaluating the efficacy of ICI monotherapy and the combination of ICIs with chemotherapy (CT) in patients with advanced rare tumors.Methods: In this retrospective cohort study, we included 93 patients treated with ICIs for NCI-defined rare tumors from the 12 cancer centers in Turkey. The primary endpoints were the overall response (ORR) and disease control rate (DCR).Results: The cohort's median age was 56, and 53.8% of the patients were male. The most frequent diagnosis was sarcoma (29%), and 81.7% of the patients were previously treated with at least one line of systemic therapy in the advanced stage. The ORR and DCR were 36.8% and 63.2%, respectively. The germ cell tumors had the lowest ORR (0%), while the Merkel cell carcinoma had the highest ORR to ICIs (57.1%). Patients treated with ICI + ICI or ICI plus chemotherapy combinations had higher ORR (55.2% vs. 27.6%, p = 0.012) and DCR (82.8% vs. 53.4%, p = 0.008). The median OS was 13.47 (95% CI: 7.79-19.15) months, and the six and 12-month survival rates were 71% and 52%. The median duration of response was 16.59 months, and the 12-month progression-free survival rate was 66% in responders. The median time-to-treatment failure was 5.06 months (95% CI: 3.42-6.71). Three patients had high-grade irAEs with ICIs (grade 3 colitis, grade 3 gastritis, and grade 3 encephalitis in one patient each).Results: The cohort's median age was 56, and 53.8% of the patients were male. The most frequent diagnosis was sarcoma (29%), and 81.7% of the patients were previously treated with at least one line of systemic therapy in the advanced stage. The ORR and DCR were 36.8% and 63.2%, respectively. The germ cell tumors had the lowest ORR (0%), while the Merkel cell carcinoma had the highest ORR to ICIs (57.1%). Patients treated with ICI + ICI or ICI plus chemotherapy combinations had higher ORR (55.2% vs. 27.6%, p = 0.012) and DCR (82.8% vs. 53.4%, p = 0.008). The median OS was 13.47 (95% CI: 7.79-19.15) months, and the six and 12-month survival rates were 71% and 52%. The median duration of response was 16.59 months, and the 12-month progression-free survival rate was 66% in responders. The median time-to-treatment failure was 5.06 months (95% CI: 3.42-6.71). Three patients had high-grade irAEs with ICIs (grade 3 colitis, grade 3 gastritis, and grade 3 encephalitis in one patient each).Conclusion: We observed over 30% ORR and a 13-month median OS in patients with rare cancers treated with ICI monotherapy or ICI plus CT combinations. The response rates to ICIs or ICIs plus CT significantly varied across different tumor types. Responding patients had over 2 years of survival, highlighting a need for further trials with ICIs for patients with rare tumors.
  • Thumbnail Image
    Article
    Citation - WoS: 6
    Citation - Scopus: 6
    Modified Docetaxel, Cisplatin, and 5-Fluorouracil Combination Regimen and Capecitabine Maintenance in Metastatic Gastric Cancer: Toxicity and Efficacy Results
    (Springer, 2022-02-02) Arslan, Cagatay; Atilla, Fatos Dilan
    Background Little progress has been made, and there is an unmet medical need for treatment of metastatic gastric cancer (MGC). Docetaxel + cisplatin + 5-fluororacil (DCF) combination is an effective regimen with high rate of toxicity and is not well tolerated. We aimed to evaluate the efficacy and toxicity of a modified DCF (mDCF) combination regimen and capecitabine maintenance in MGC. Method Data of MGC patients were treated with first-line mDCF regimen (two weekly docetaxel 60 mg/m(2) day 1 iv, cisplatin 50 mg/m(2) day 1 iv, 5-fluouracil 400 mg/m(2) day 1 iv push, 2400 mg/m(2); day 1-day 2 iv infusion, leucovorin 400 mg/m(2) day 1 iv push) were recorded. Capecitabine maintenance was given as 2500 mg/m(2)/ day 1-day 14 po, every 3 weeks, to patients who do not have progressive disease and grade 3 treatment-related toxicity. A retrospective analysis was made. Results Forty patients were included. Mean age was 53 +/- 11. Thirty-two patients had de novo metastasis. All patients' performance status was ECOG 1 or 2 (32/8). Median number of mDCF cycles given was 9 (min-max: 1-23). Overall response rate was 47.5%. Ten patients (25%) received capecitabine maintenance. Grade 3/4 toxicity was seen in 20 patients (50%). Hematologic grade 3/4 toxicity occurred in 13 patients (32.5%), and grade 3/4 neutropenia occurred in 11 patients (27.5%) and in 15 cycles. Nonhematologic grade 3/4 toxicity was seen in 7 patients (17.5%). Median follow-up time was 17.2 months. Median time to progression (TTP) was 10.8 +/- 1.9 months (95% CI: 6.89-14.64). Median overall survival was 14.7 +/- 1.73 months (95% CI: 11.30-18.10). Conclusions mDCF protocol was a tolerable chemotherapy regimen for the first-line treatment of MGC with higher ORR and longer TTP compared to standard DCF protocol. Capecitabine maintenance might increase TTP.
  • Thumbnail Image
    Article
    Citation - WoS: 6
    Citation - Scopus: 5
    Nivolumab in Metastatic Renal Cell Carcinoma: Results From the Turkish Oncology Group Kidney Cancer Consortium Database
    (Future Medicine Ltd, 2021-11-02) Yekeduz, Emre; Erturk, Ismail; Tural, Deniz; Karadurmus, Nuri; Karakaya, Serdar; Hizal, Mutlu; Arikan, Rukiye; Arslan, Cagatay; Hlzal, Mutlu; Ürün, Yüksel
    Lay abstract Nivolumab is an immune checkpoint inhibitor (ICI) that blocks the communication between T cells and cancer cells and instead activates T cells to fight against cancer. Metastatic renal cell carcinoma (mRCC) is one of the most susceptible tumors to ICIs. The Checkmate 025 trial showed the efficacy of nivolumab in patients with previously treated mRCC. In this real-world study, 173 patients with mRCC were treated with nivolumab in the second line and beyond. Nivolumab was effective in the real-world setting without additional safety concerns. Aim: The authors present real-world data on the efficacy and safety of nivolumab in patients with metastatic renal cell carcinoma (mRCC). Methods: The Turkish Oncology Group Kidney Cancer Consortium (TKCC) database includes patients with mRCC from 13 cancer centers in Turkey. Patients with mRCC treated with nivolumab in the second line and beyond were extracted from the TKCC database. Results: A total of 173 patients were included. The rates of patients treated with nivolumab in the second, third, fourth and fifth lines were 47.4%, 32.4%, 14.5% and 5.7%, respectively. The median overall survival and progression-free survival were 24.2 months and 9.6 months, respectively. Nivolumab was discontinued owing to adverse events in 11 (6.4%) patients. Conclusion: Nivolumab was effective in patients with mRCC and no new safety signal was observed.
  • Thumbnail Image
    Conference Object
    Romiplostim for Chemotherapy-Induced Thrombocytopenia (cit) in Solid Tumors: Two Phase Iii, International, Randomized Controlled Trials (rct)
    (Elsevier, 2022-09) Al-Samkari, H.; Geredeli, C.; Arslan, C.; Korantzis, I.; Dogu, G. G.; Nechaeva, M.; Salgado Fernandez, M.; Soff, G. A.
    [Abstract Not Available]
  • Thumbnail Image
    Conference Object
    Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Colorectal, Gastroesophageal, and Pancreatic Cancers: A Global, Phase 3, Randomized, Placebo-Controlled Trial (RCT)
    (Lippincott Williams & Wilkins, 2025-06) Munoz, Cesar; Soff, Gerald A.; Korantzis, Ippokratis; Al-Samkari, Hanny; Gonzalez Astorga, Beatriz; Arslan, Cagatay; Geredeli, Caglayan